CME: The Growing Burden of HPV-Associated Cancers

The Growing Burden of HPV-Associated Cancers

The Growing Burden of HPV-Associated Cancers

HPV accounts for over 80 percent of oropharyngeal cancers and almost all cervical cancers. But luckily, there are treatment options on the horizon.

Available credits: 0.25

Time to complete: 15 Minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    As the burden of HPV-associated cancers like cervical cancer and oropharyngeal cancers, which are a subset of squamous cell cancer of the head and neck (SCCHN), continues to grow, are there emerging treatments that may lead to more optimal outcomes? Join oncology experts in both areas of focus as they discuss treatment approaches for SCCHN and cervical cancer.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, The Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Omid Hamid, MD
    Chief, Translational Research & Immunotherapy
    Director, Cutaneous Oncology
    The Angeles Clinic & Research Institute
    Los Angeles, CA

    Dr. Hamid has disclosed he receives consulting fees from Amgen, Bristol-Myers Squibb, Merck, Novartis, and Roche; and is a member of the speaker bureau for Amgen, Array, Bristol-Myers Squibb, Genentech, Novartis, and Sanofi/Regeneron.

    He does contracted research for Amgen, Arcus, Astellas, Astra Zeneca, Bristol-Myers Squibb, Celldex, CytomX, Genentech, GSK, Immunocore, Incyte, Iovance, Merck, Merck-Serono, MedImmune, NextCure, Novartis, Parker Institute, Pfizer, Polynoma, Regeneron, and Roche.

    Susana M. Campos, MD, MPH
    Assistant Professor of Medicine
    Dana Farber Cancer Institute
    Boston, MA 

    Dr. Campos has disclosed she receives consulting fees from Esai, Serono, and Tesaro.

    Robert Ferris, MD
    UPMC Hillman Cancer Center
    Pittsburgh, PA

    Dr. Ferris has disclosed he is on the Advisory Board for Amgen, Astra-Zeneca/MedImmune, Bristol-Myers Squibb,  EMD Serono, GlaxoSmithKline, Lilly, Merck, Numb Therapeutics AG, Oncorus, Inc. Pfizer, PPD, Regeneron Pharmaceuticals, Inc., and Tesaro; and receives consulting fees from Aduro Biotech, Inc., Bain Capital Life Sciences, Iovance Biotherapeutics, Inc., Ono Pharmaceutical Co. Ltd, Torque Therapeutics Inc, and TTMS. He does contracted research for Astra-Zeneca/MedImmune, Bristol-Myers Squibb, Merck, and VentiRx Pharmaceuticals.

    Reviewers/Content Planners/Authors:

    • Sean T. Barrett has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Barry A. Fiedel, PhD has nothing to disclose.
    • John Pirovitz has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Describe the epidemiology and burden of disease of HPV-associated cancers.
    • Identify emergent therapeutic mechanisms of action that may offer novel approaches to managing HPV-associated cancers.
  • Target Audience

    This activity is designed to meet the educational needs of Surgical Oncologist, Medical Oncologists, Hematologists, Nurse Practitioners, Physician Assistants, and any Healthcare Professionals treating patients with cancer.

  • Accreditation and Credit Designation Statements

    The Global Learning Collaborative, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Global Learning Collaborative, Inc. designates this enduring material for a maximum of .25 creditsAMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at

  • Provider

    GLC designs educational activities based on evidence-based medicine, needs and gaps analyses, learner feedback, and more. Its mission is to serve as an innovative and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

  • Commercial Support

    This educational activity is supported by an independent grant from the Healthcare business of Merck KGaA, Darmstadt, Germany.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of GLC you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

    Disclaimer: Some products discussed in this activity may not have received regulatory approval by the US FDA for the treatment of patients. The FDA has stated that “good medical practice and the best interests of the patient require that physicians use legally available drugs, biologics and devices according to their best knowledge and judgement”. 

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments



We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free